ADC Therapeutics Appoints CEO
News Jun 23, 2015
ADC Therapeutics has announced the appointment of Dr. Chris Martin as its Chief Executive Officer.
Dr. Martin was co-founder of Spirogen Ltd and its Chief Executive Officer leading up to the sale of Spirogen to MedImmune, the global biologics research and development arm of Astra Zeneca in October 2013 for $440 million in upfront and deferred consideration.
Dr. Martin continued as CEO of Spirogen, and became both a member of Medimmune’s Management Leadership Team and AstraZeneca’s Senior Leaders Group. Dr. Martin will continue to advise Medimmune as a consultant.
Dr. Martin played an important role in the formation of ADC Therapeutics in 2012, and has served on its board of directors since its founding. He is a recognized leader in the Antibody Drug Conjugates space, and his leadership of Spirogen led to Spirogen being awarded the Best Scientific Innovation Award in 2014 and Dr Martin being voted by industry peers the winner of the overall ‘Individual Input to the Industry in 2013/2014’ at the World ADC Awards.
Dr. Martin replaces Michael Forer who has served as CEO of the Company since its formation. Mr. Forer is a Partner in the private equity firm Auven Therapeutics and was the lead investor on behalf of Auven for its majority investments in both Spirogen Ltd and ADC Therapeutics.
Mr. Forer becomes Vice Chairman of ADC Therapeutics, and will continue to work with the Company as Executive Vice President focused on its public markets capital strategy, business and finance activities.
Dr. Peter B. Corr, Chairman of the Board of ADCT and co-founder and Managing General Partner of Auven Therapeutics, said: “Chris played an important role together with Michael Forer in the founding of ADC Therapeutics, and its business plan to develop proprietary PBD-based ADCs under license from Spirogen. He has contributed significantly to the business both as a board member and shareholder, and we are delighted that he has now joined the Company as CEO as we move forward with 7 PBD-based ADCs into clinical development over the next two years. We believe that PBD-based ADCs are the next-generation of cancer drugs with the potential to make a large impact on cancer patients worldwide.”
Dr. Martin said: “The Company is entering an exciting phase of clinical development, having recently filed its first IND for a clinical trial in lymphoma and its second IND to be filed later this year. Michael has been an important supporter to the success of both Spirogen and ADC Therapeutics, and I thank him for his leadership to-date. I look forward to working even more closely with the ADCT team as well as with our investors and collaborators, to realize the potential of our ADC drugs.”
Malaria Prevention: New Antibody Targets Unique Binding SiteNews
Scientists have discovered a human antibody that, when tested in mice, prevented malaria infection by binding a specific portion of a surface protein found in almost all strains of the malaria parasite worldwide.READ MORE
Alternative to Antibiotics: Antibody Approach for Treating Multidrug-Resistant Bacterial InfectionsNews
Researchers are developing a promising alternative to antibiotic treatment for infections caused by Klebsiella pneumoniae bacteria resistant to carbapenem antibiotics. The approach uses antibodies to target the K. pneumoniae protective capsule polysaccharide.READ MORE
Combination Drug Trial Launched to Eradicate B-Cell MalignanciesNews
Researchers at University of California San Diego School of Medicine, in collaboration with local biotechnology company Oncternal Therapeutics, have launched a phase Ib/II clinical trial to evaluate the combined effectiveness of a standard of care drug with a novel monoclonal antibody that target B-cell malignancies, which include leukemias and lymphomas.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Pharmacy and Clinical Research
Jul 16 - Jul 17, 2018